ANDUSOMERAN
UNII 4F9QRS7ZV2

Substance Identification & Data

This profile provides standardized clinical and technical data for Andusomeran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 4F9QRS7ZV2.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2918977-08-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

4F9QRS7ZV2

CAS Registry Number

2918977-08-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ANDUSOMERAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203097

National Cancer Institute reference terminology for clinical and research data.

INN ID

13097

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

nucleicAcid

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Andusomeran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ANDUSOMERAN

Common Names & Synonyms

ANDUSOMERAN [INN]

ANDUSOMERAN [WHO-DD]

CX-038839 (COVID-19 OMICRON SUBVARIANT KRAKEN) PREFUSION SPIKE PROTEIN MRNA

CX-038839 (COVID-19 OMICRON SUBVARIANT XBB.1.5) PREFUSION SPIKE PROTEIN MRNA

MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING A FULL-LENGTH, CODON-OPTIMISED PRE-FUSION STABILISED CONFORMATION VARIANT (K982P AND V983P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) SPIKE (S) GLYCOPROTEIN (OMICRON VARIANT XBB.1.5; BASED UPON GISAID: EPI_ISL_15948646) FURTHER OPTIMIZED BY TWO ADDITIONAL STOP CODONS, FLANKED BY AN ARTIFICIAL 5' UNTRANSLATED REGION (UTR) AND A 3' UTR DERIVED FROM THE HUMAN ALPHA GLOBIN GENE (HBA1) MODIFIED TO CONTAIN AN IDENTIFICATION AND RATIO (IDR) SEQUENCE TO ENABLE IDENTIFICATION AND RELATIVE RATIO DETERMINATION OF INDIVIDUAL RNA COMPONENTS IN A MULTIVALENT MRNA VACCINE, AND TERMINATED BY A 3' POLYADENYLATION (POLYA) TAIL; CONTAINS N1-METHYLPSEUDOURIDINE INSTEAD OF URIDINE (ALL-U>M 1.PSI.)

RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-GM)-CAPPED ALL URIDINE->N1-METHYLPSEUDOURIDINE-SUBSTITUTED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 PRE-FUSION SPIKE GLYCOPROTEIN (982-PROLINE,983-PROLINE) XBB.1.5 VARIANT PLUS 5'- AND 3'-UNTRANSLATED FLANKING REGION-CONTAINING POLY(A)-TAILED MESSENGER CX-038839), INNER SALT

Technical Codes

CX-038839

CX-038839 OMICRON (XBB.1.5)

External Clinical & Regulatory Resources

Previous UNII4F9KUA0T4D

Next UNII4F9R2P2HA3